Medical University Innsbruck
i-med.ac.atTotal trials
178
Active
47
Phase 3
7
Total enrollment
260,058
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| neoadjuvant therapy with Pembrolizumab/Lenvatinib | — | — | — | — | — | 1 | |
| Adjuvant Treatment Phase | — | — | — | — | — | 1 | |
| Alfa1 Antitrypsin | — | — | — | — | — | 1 | |
| Blood sampling | — | — | — | — | — | 2 |
Next readouts
- 2021-03-01
- 2023-12
- 2025-07
Top conditions
- COVID-196
- Cardiovascular Diseases4
- Atherosclerosis4
- Major Depressive Disorder3
- Healthy3
- Covid193
- Heart Failure3
- Fallopian Tube Cancer2
Frequently asked questions about Medical University Innsbruck
- How many clinical trials does Medical University Innsbruck have on ClinicalTrials.gov?
- Medical University Innsbruck is listed as the lead sponsor on 178 clinical trials in ClinicalTrials.gov, 47 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Medical University Innsbruck's trials are in Phase 3?
- 7 of Medical University Innsbruck's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Medical University Innsbruck focus on?
- Medical University Innsbruck's most-studied conditions on ClinicalTrials.gov are COVID-19, Cardiovascular Diseases, Atherosclerosis, Major Depressive Disorder, Healthy.
- When are Medical University Innsbruck's next clinical trial readouts?
- Medical University Innsbruck has 3 upcoming primary-completion readouts tracked here; the soonest is “Connective Tissue Diseases and Lung Manifestations”, expected around 2021-03-01.